Rl. Spitzer et al., Jet lag: Clinical features, validation of a new syndrome-specific scale, and lack of response to melatonin in a randomized, double-blind trial, AM J PSYCHI, 156(9), 1999, pp. 1392-1396
Objective: The goals of this study were to validate a new rating scale for
measuring severity of jet lag and to compare the efficacy of contrasting me
latonin regimens to alleviate jet lag. Method: This was a randomized, doubl
e-blind trial of placebo and three alternative regimens of melatonin (5.0 m
g at bedtime, 0.5 mg at bedtime, and 0.5 mg taken on a shifting schedule) f
or jet lag. The subjects were 257 Norwegian physicians who had visited New
York for 5 days. Jet lag ratings were made on the day of travel from New Yo
rk back to Oslo (6 hours eastward) and for the next 6 days in Norway. The m
ain outcome measures were scale and item scores from a new, syndrome-specif
ic instrument, the Columbia Jet Lag Scale, that identifies prominent daytim
e symptoms of jet lag distress. Results: There was a marked increase in tot
al jet lag score in all four treatment groups on the first day at home, fol
lowed by progressive improvement over the next 5 days. However, there were
no significant group differences or group-by-time interactions. In addition
, there was no group effect for sleep onset, time of awakening, hours slept
, or hours napping. Ratings on a summary jet lag item were highly correlate
d with total jet lag scores (from a low of r=0.54 on the day of travel to a
high of r=0.80 on day 3). The internal consistency of the total jet lag sc
ore was high on each day of the study. Conclusions: The use of melatonin fo
r preventing jet lag needs further study.